Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Gardini, Andrea Casadei ^a   Foca, Flavia ^a   Scartozzi, Mario ^b   Silvestris, Nicola ^c   Tamburini, Emiliano ^d   Faloppi, Luca ^b   Brunetti, Oronzo ^c   Rudnas, Britt ^a   Pisconti, Salvatore ^e   Valgiusti, Martina ^a   Marisi, Giorgia ^a   Foschi, Francesco Giuseppe ^f   Ercolani, Giorgio ^g,h   Tassinari, Davide ^d   Cascinu, Stefano ⁱ   Frassineti, Giovanni Luca ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d Hospital of Rimini   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f Ospedale per gli Infermi di Faenza   (Italy)

^g MORGAGNI PIERANTONI HOSPITAL   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE;

ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, METRONOMIC; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CAPECITABINE; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85012294463     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42499     Document Type: Article

References (28)

1. Faloppi, L. et al. Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 37, 169-177 (2011)
2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359, 378-390 (2008).
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guide-lines: management of hepatocellular carcinoma. Journal of Hepatology. 56, 908-43 (2012).
4. Shao, Y. Y. et al. Prognosis of patients with advanced hepatocel-lular carcinoma who failed first-line systemic therapy. Journal of Hepatology. 60, 313-8 (2014).
5. Reig, M. et al. Postprogression survival of patients withadvanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology. 58, 2023-31 (2013).
6. Walko, C. M. et al. Capecitabine: a review. Clinical Therapeutics. 27, 23-44 (2005).
7. Cramarossa, G., Lee, E. K., Sivanathan, L. et al. A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. Biomarkersin Medicine. 8, 893-911 (2014).
8. Takimoto, C. H. Maximum tolerated dose: clinical endpoint for a bygone era? Target Oncol. 4, 143-7 (2009).
9. Cecconetto, L. et al. Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy. Tumori. 100(3), e79-82 (2014).
10. Gnoni, A. et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. Jul. 95(1), 46-61 (2015).
11. Brandi, G. et al. Durable complete response of hepatocel-lular carcinoma after metronomic capecitabine. Tumori. 96, 1028-30 (2010).
12. Patt, Y. Z. et al. Oral capecitabine for the treatmentof hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 101, 578-86 (2004).
13. Xia, Y. et al. Adjuvant therapy with capecitabine postpones recurrenceof hepatocellular carcinoma after curative resection: a randomized controlled trial. Annals of Surgical Oncology. 17, 3137-44 (2010).
14. Ballardini, P. et al. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma. Tumori. 96, 768-70 (2010).
15. Alessandro, G. et al. Metronomic capecitabine as second-line treatment in hepatocellularcarcinoma after sorafenib failure. Dig Liver Dis. 47, 518-22 (2015).
16. Brandi, G. et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist. 18, 1256-7 (2013).
17. Lencioni, R. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30, 52-60 (2010).
18. Santoro, A. et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study The Lancet Oncology. 14, 55-6 (2013).
19. Casadei Gardini, A. et al. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opin Pharmacother. 16, 2719-25 (2015).
20. Lee, J. L. et al. Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis. J Gastroenterol Hepatol. 23, 811-6 (2008).
21. Cantarini, M. C. et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 101, 91-8 (2006).
22. Reig, M. et al. Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design Hepatology. 58, 2023-31 (2013).
23. Gressett, S. M. et al. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 12, 131-41 (2006).
24. Hofheinz, R. D. et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 107, 1678-83 (2012).
25. Stintzing, S. et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: Results from the German AIO KRK-0104 trial. Br J Cancer. 105, 206-11 (2011).
26. Bruix, J. et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma progressing on sorafenib: Results of the international, randomized phase 3 RESORCE trial. ESMO World Congress on Gastrointestinal Cancer. Abstract LBA-03, (2016).
27. Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer. Liver Cancer. 3, 125-31 (2014).
28. Kudo, M. Why does every hepatocellular carcinoma clinical trial using molecular target ed agents fail? Liver Cancer. 1, 59-60 (2012).